长期使用硫唑嘌呤治疗重症肌无力的缓解与复发：一项双向性研究。
Remission And relapse of myasthenia gravis on long-term azathioprine: An ambispective study.
作者信息
Gupta Anirban, Goyal Vinay, Srivastava Achal Kumar, Shukla Garima, Behari Madhuri
机构信息
Department of Neurology, Cardiothoracic and Neurosciences Centre, Room 706, All India Institute of Medical Sciences, New Delhi, 110029, India.
出版信息
Muscle Nerve. 2016 Sep;54(3):405-12. doi: 10.1002/mus.25052.
INTRODUCTION
Azathioprine (AZA) is commonly used in myasthenia gravis (MG). Treatment may be prolonged, entailing significant risks and avoidable costs.
METHODS
We reviewed remission, relapse, and side-effect profiles in MG patients on AZA during treatment and after tapering off. We conducted an ambispective study and analyzed remission, relapse rates, and side-effect profiles in 117 MG patients on AZA.
RESULTS
Thirty-nine patients (33.3%) achieved remission, and 36 (30.8%) achieved complete stable remission (CSR), with a 33% relapse rate. No AZA side effects were seen in 95 (81%) patients. Only duration of disease of >10 years (odds ratio 9.5, 95% confidence interval 2.4-36.9, P = 0.001) was significantly associated with remission.
CONCLUSIONS
AZA is well tolerated by MG patients, and about 30% go into CSR on long-term AZA. Muscle Nerve, 2016 Muscle Nerve 54: 405-412, 2016.
引言
硫唑嘌呤（AZA）常用于治疗重症肌无力（MG）。治疗过程可能会延长，带来重大风险和可避免的费用。
方法
我们回顾了MG患者在接受AZA治疗期间及逐渐减药后的缓解、复发及副作用情况。我们进行了一项前瞻性研究，并分析了117例接受AZA治疗的MG患者的缓解情况、复发率及副作用情况。
结果
39例患者（33.3%）实现缓解，36例（30.8%）实现完全稳定缓解（CSR），复发率为33%。95例（81%）患者未出现AZA副作用。只有病程>10年（优势比9.5，95%置信区间2.4 - 36.9，P = 0.001）与缓解显著相关。
结论
MG患者对AZA耐受性良好，约30%的患者在长期使用AZA后进入完全稳定缓解状态。《肌肉与神经》，2016年 肌肉与神经54: 405 - 412，2016年。
Zotero 插件